BTG2016 Scientific Agenda: Session DAY 2
Sunday, February 28, 2016
CLICK HERE FOR CORPORATE DAY: FEB 26
CLICK HERE FOR DAY 1 AGENDA: FEB 27
REGISTRATION DESK: 6:30 AM - 2:00 PM
PLENARY SESSION: 8:00 AM - 5:00 PM
8:00 AM-9:00 AM MYELOPROLIFERATIVE DISORDERS
Moderators: Liansheng Zhang & Pankaj Malhotra
8:00 AM
Management of lower-risk MDS without del5q and refractory to ESAs
Zong Hong Shao, MD (Tianjin Medical University General Hospital, Tianjin, China)
8:20 AM
IPSS, DIPSS, DIPSS-Plus, MISPS, GIPSS: making sense of the tangled web of prognostic scoring systems in MF
Raymond Wong, MD (Chinese University, Hong Kong)
8:30 AM
Should JAK2 inhibitors be used for lower-risk MF, or only on-label (higher-risk)?
Sharat Damodar, MD (NH Narayana Multi-specialty Clinic, Bangalore, India)
8:40 AM
Treatment Updates for MDS
Jie Jin , MD (The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China)
9:00 AM – 9:20 AM KIAN ANG MEMORIAL LECTURE
The value of collaborative research in oncology
Moderators: Xiaojun Huang & Surapol Issaragrisil
Robert Orlowski, MD, PhD (MD Anderson Cancer Center, Houston, USA)
9:20 AM – 10:00 AM BEST ORAL ABSTRACT PRESENTATION
Moderator: Kaiyan Liu & Simrit Parmar
10:00 AM-10:20 AM Coffee Break/Poster Viewing
10:20 AM-11:00 AM HODGKIN’S LYMPHOMA
Moderators: Ting Liu & Chepsy Philip
10:20 AM
What is the standard of care for limited stage Hodgkin's Lymphoma?
Daryl Tan, MD (Raffles Hospital, Singapore)
10:30 AM
Advanced stage Hodgkin disease: recent approaches
Morton Coleman, MD (Cornell University, New York, USA)
10:40 AM
Clinical Trials Update: PD-1 Blockade in HL
Frederick Hagemeister, MD (MD Anderson Cancer Center, Houston, USA)
11:00 AM-12:00 PM CHRONIC MYELOID LEUKEMIA
Moderators : Jianmin Wang & Sharat Damodar
11:00 AM
How should chronic-phase CML management be influenced by RT-PCR results at 3 months and beyond?
Dong Wook Kim, MD (Seoul St. Mary Hospital, Seoul, S. Korea)
11:20 AM
Who should still be transplanted for CML in 2015?
David Ritchie, MD, PhD (Royal Melbourne Hospital, Melbourne, Australia)
11:40 AM
Monitoring Chronic Myeloid Leukemia in the Real World
Qian Jiang, MD (Peking University, Beijing, China)
12:00 - 2:00 LUNCH SYMPOSIUM
12:00 PM-1:00 PM AMGEN Lunch Session
Advances in Proteasome Inhibition in Multiple Myeloma
12-00-12.05 (5 min)
Opening and Welcome
Prof Hou Jian, Shanghai Changzheng Hospital, China
12:05-12:30 (25 min)
The Evolving Role of Proteasome Inhibition in Multiple Myeloma
Dr. Robert Z Orlowski, The University of Texas MD Anderson Cancer Center, US
12:30-12:55 (25 min)
New Strategies in Combination Therapies for Multiple Myeloma in Asia Patients
Dr. Cheng-Shyong Chang, Changhua Christian Hospital, Taiwan
12:55-13:00 (5 min)
Q&A
All
1:00 PM-2:00 PM XIAN JANSSEN Lunch Symposium:
Precision therapy for MDS
Moderator: Juan Li, MD
Speaker: Zong Hong Shao, MD (Tianjin Medical University General Hospital, Tianjin, China)
2:00 PM – 2:20 PM CHRONIC LYMPHOCYTIC LEUKEMIA
Moderators: Jianda Hu & Dharma Choudhary
2:00 PM
Debate Session: What is the best frontline regimen for a CLL patient aged 60 who requires therapy?
Fludarabine-Cytoxan-Rituxan: Jian Yong Li, MD (First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, China)
Ibrutinib-based treatment without chemotherapy: Pankaj Malhotra, MD (PGIMER, Chandigarh, India)
2:20 PM – 3:00 PM ACUTE MYELOID LEUKEMIA
Moderators: Zimin Sun & Young-Ho Lee
2:20 PM
Optimal management of newly diagnosed Elderly AML
Swami Iyer, MD (Houston Methodist Cancer Center, Houston, USA)
2:35 PM
Novel agents for treatment of AML
Jian Xiang Wang, MD, PhD (Peking Union of Medical College, Tianjin, China)
2:50 PM
Upfront allogeneic stem cell transplant for standard risk AML
Xiao Jun Huang, MD, PhD (Peking university, Beijing, China)
3:05 PM – 3:40 PM ACUTE LYMPHOCYTIC LEUKEMIA
Moderators: Jiong Hu & Govind Babu
3:05 PM
Optimal induction for Ph+ ALL
Depei Wu, MD (First Affiliated hospital of Soochow University, China)
3:20 PM
Immunotherapy for ALL
David Ritchie, MD, PhD (Royal Melbourne Hospital, Australia)
3:40 PM ADJOURN
CLICK HERE FOR DAY 1 AGENDA: FEB 27
REGISTRATION DESK: 6:30 AM - 2:00 PM
PLENARY SESSION: 8:00 AM - 5:00 PM
8:00 AM-9:00 AM MYELOPROLIFERATIVE DISORDERS
Moderators: Liansheng Zhang & Pankaj Malhotra
8:00 AM
Management of lower-risk MDS without del5q and refractory to ESAs
Zong Hong Shao, MD (Tianjin Medical University General Hospital, Tianjin, China)
8:20 AM
IPSS, DIPSS, DIPSS-Plus, MISPS, GIPSS: making sense of the tangled web of prognostic scoring systems in MF
Raymond Wong, MD (Chinese University, Hong Kong)
8:30 AM
Should JAK2 inhibitors be used for lower-risk MF, or only on-label (higher-risk)?
Sharat Damodar, MD (NH Narayana Multi-specialty Clinic, Bangalore, India)
8:40 AM
Treatment Updates for MDS
Jie Jin , MD (The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China)
9:00 AM – 9:20 AM KIAN ANG MEMORIAL LECTURE
The value of collaborative research in oncology
Moderators: Xiaojun Huang & Surapol Issaragrisil
Robert Orlowski, MD, PhD (MD Anderson Cancer Center, Houston, USA)
9:20 AM – 10:00 AM BEST ORAL ABSTRACT PRESENTATION
Moderator: Kaiyan Liu & Simrit Parmar
10:00 AM-10:20 AM Coffee Break/Poster Viewing
10:20 AM-11:00 AM HODGKIN’S LYMPHOMA
Moderators: Ting Liu & Chepsy Philip
10:20 AM
What is the standard of care for limited stage Hodgkin's Lymphoma?
Daryl Tan, MD (Raffles Hospital, Singapore)
10:30 AM
Advanced stage Hodgkin disease: recent approaches
Morton Coleman, MD (Cornell University, New York, USA)
10:40 AM
Clinical Trials Update: PD-1 Blockade in HL
Frederick Hagemeister, MD (MD Anderson Cancer Center, Houston, USA)
11:00 AM-12:00 PM CHRONIC MYELOID LEUKEMIA
Moderators : Jianmin Wang & Sharat Damodar
11:00 AM
How should chronic-phase CML management be influenced by RT-PCR results at 3 months and beyond?
Dong Wook Kim, MD (Seoul St. Mary Hospital, Seoul, S. Korea)
11:20 AM
Who should still be transplanted for CML in 2015?
David Ritchie, MD, PhD (Royal Melbourne Hospital, Melbourne, Australia)
11:40 AM
Monitoring Chronic Myeloid Leukemia in the Real World
Qian Jiang, MD (Peking University, Beijing, China)
12:00 - 2:00 LUNCH SYMPOSIUM
12:00 PM-1:00 PM AMGEN Lunch Session
Advances in Proteasome Inhibition in Multiple Myeloma
12-00-12.05 (5 min)
Opening and Welcome
Prof Hou Jian, Shanghai Changzheng Hospital, China
12:05-12:30 (25 min)
The Evolving Role of Proteasome Inhibition in Multiple Myeloma
Dr. Robert Z Orlowski, The University of Texas MD Anderson Cancer Center, US
12:30-12:55 (25 min)
New Strategies in Combination Therapies for Multiple Myeloma in Asia Patients
Dr. Cheng-Shyong Chang, Changhua Christian Hospital, Taiwan
12:55-13:00 (5 min)
Q&A
All
1:00 PM-2:00 PM XIAN JANSSEN Lunch Symposium:
Precision therapy for MDS
Moderator: Juan Li, MD
Speaker: Zong Hong Shao, MD (Tianjin Medical University General Hospital, Tianjin, China)
2:00 PM – 2:20 PM CHRONIC LYMPHOCYTIC LEUKEMIA
Moderators: Jianda Hu & Dharma Choudhary
2:00 PM
Debate Session: What is the best frontline regimen for a CLL patient aged 60 who requires therapy?
Fludarabine-Cytoxan-Rituxan: Jian Yong Li, MD (First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, China)
Ibrutinib-based treatment without chemotherapy: Pankaj Malhotra, MD (PGIMER, Chandigarh, India)
2:20 PM – 3:00 PM ACUTE MYELOID LEUKEMIA
Moderators: Zimin Sun & Young-Ho Lee
2:20 PM
Optimal management of newly diagnosed Elderly AML
Swami Iyer, MD (Houston Methodist Cancer Center, Houston, USA)
2:35 PM
Novel agents for treatment of AML
Jian Xiang Wang, MD, PhD (Peking Union of Medical College, Tianjin, China)
2:50 PM
Upfront allogeneic stem cell transplant for standard risk AML
Xiao Jun Huang, MD, PhD (Peking university, Beijing, China)
3:05 PM – 3:40 PM ACUTE LYMPHOCYTIC LEUKEMIA
Moderators: Jiong Hu & Govind Babu
3:05 PM
Optimal induction for Ph+ ALL
Depei Wu, MD (First Affiliated hospital of Soochow University, China)
3:20 PM
Immunotherapy for ALL
David Ritchie, MD, PhD (Royal Melbourne Hospital, Australia)
3:40 PM ADJOURN